# Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

Study · id `cardio:ct-nct01887600` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01887600](<https://clinicaltrials.gov/study/NCT01887600>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01887600

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 594 participants.

## Technical summary

Registry record NCT01887600. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-03 (actual); primary completion 2017-11-01 (actual). Results posted on 2020-12-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 594 participants (enrolled count; ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Started: 2013-09-03 (actual) (ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Primary completion: 2017-11-01 (actual) (ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Completion: 2017-11-01 (actual) (ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Results first posted: 2020-12-17 (ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Countries: Belarus; Belgium; Bulgaria; Colombia; Dominican Republic; Estonia; Georgia; Greece; Guatemala; Hungary; Italy; Panama; Peru; Poland; Romania; Russia; Serbia; South Africa; Spain; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01887600, source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01887600-2024-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
- Acronym: ALPS
- Condition: Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Intervention (Drug): Roxadustat
- Intervention (Drug): Placebo
- Lead sponsor: Astellas Pharma Europe B.V.
- Lead sponsor class: INDUSTRY
- Collaborator: Kyntra Bio
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)
- Registry lists this organization as a collaborator: Kyntra Bio (`cardio:org-kyntra-bio`)

## Provenance

Content hash: 94d7528cd45a4128ba84518152befc5a7db7e9979bcdc9fd35b9e111f3f05397
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
